• Gerard J Criner, Jean Bourbeau, Rebecca L Diekemper, Daniel R Ouellette, Donna Goodridge, Paul Hernandez, Kristen Curren, Meyer S Balter, Mohit Bhutani, Pat G Camp, Bartolome R Celli, Gail Dechman, Mark T Dransfield, Stanley B Fiel, Marilyn G Foreman, Nicola A Hanania, Belinda K Ireland, Nathaniel Marchetti, Darcy D Marciniuk, Richard A Mularski, Joseph Ornelas, Jeremy D Road, and Michael K Stickland.
• Temple University School of Medicine, Philadelphia, PA. Electronic address: gerard.criner@tuhs.temple.edu.
• Chest. 2015 Apr 1; 147 (4): 894942894-942.

BackgroundCOPD is a major cause of morbidity and mortality in the United States as well as throughout the rest of the world. An exacerbation of COPD (periodic escalations of symptoms of cough, dyspnea, and sputum production) is a major contributor to worsening lung function, impairment in quality of life, need for urgent care or hospitalization, and cost of care in COPD. Research conducted over the past decade has contributed much to our current understanding of the pathogenesis and treatment of COPD. Additionally, an evolving literature has accumulated about the prevention of acute exacerbations.MethodsIn recognition of the importance of preventing exacerbations in patients with COPD, the American College of Chest Physicians (CHEST) and Canadian Thoracic Society (CTS) joint evidence-based guideline (AECOPD Guideline) was developed to provide a practical, clinically useful document to describe the current state of knowledge regarding the prevention of acute exacerbations according to major categories of prevention therapies. Three key clinical questions developed using the PICO (population, intervention, comparator, and outcome) format addressed the prevention of acute exacerbations of COPD: nonpharmacologic therapies, inhaled therapies, and oral therapies. We used recognized document evaluation tools to assess and choose the most appropriate studies and to extract meaningful data and grade the level of evidence to support the recommendations in each PICO question in a balanced and unbiased fashion.ResultsThe AECOPD Guideline is unique not only for its topic, the prevention of acute exacerbations of COPD, but also for the first-in-kind partnership between two of the largest thoracic societies in North America. The CHEST Guidelines Oversight Committee in partnership with the CTS COPD Clinical Assembly launched this project with the objective that a systematic review and critical evaluation of the published literature by clinical experts and researchers in the field of COPD would lead to a series of recommendations to assist clinicians in their management of the patient with COPD.ConclusionsThis guideline is unique because it provides an up-to-date, rigorous, evidence-based analysis of current randomized controlled trial data regarding the prevention of COPD exacerbations.

11 keywords...

hide…